Prepaid product supply Contract With Customer, Liability, Revenue Invoiced As Prepayments For Product Supply, Current Contract With Customer, Liability, Revenue Invoiced As Prepayments For Product Supply, Current Award Timing Predetermined Award Timing Predetermined [Flag] Entity File Number Entity File Number Additional Paid-In Capital Additional Paid-in Capital [Member] Tabular List, Table Tabular List [Table Text Block] Restricted stock units exercisable (vested and deferred) (shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Exercisable, Number Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Exercisable, Number Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Purchases of investments Payments to Acquire Short-Term Investments Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Research and development tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Licensing revenue License License [Member] XPHOZAH Product, XPHOZAH [Member] Product, XPHOZAH Adjustment to Compensation: Adjustment to Compensation [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Revenue Revenue from Contract with Customer [Text Block] Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Issuance of common stock upon vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Issuance of common stock under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Total current Current Income Tax Expense (Benefit) Elizabeth Grammer [Member] Elizabeth Grammer Adjustment to Compensation, Amount Adjustment to Compensation Amount Concentration risk (percent) Concentration Risk, Percentage Unamortized discount and debt issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Schedule of Noncurrent Inventory Schedule of Inventory, Noncurrent [Table Text Block] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Stock options Options to purchase common stock Share-Based Payment Arrangement, Option [Member] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Percent Effective Income Tax Rate Reconciliation, Percent [Abstract] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Cash, Cash Equivalents and Short-Term Investments Cash, Cash Equivalent, and Short-Term Investment [Text Block] Non-cash royalty revenue related to the sale of future royalties Non-Cash Royalty Related To Sale Of Future Royalties Non-Cash Royalty Related To Sale Of Future Royalties Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Insider Trading Policies and Procedures [Line Items] New York NEW YORK Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Issuance of common stock in at-the-market offering (in shares) Common stock sold and issued (in shares) Stock Issued During Period, Shares, New Issues Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Liabilities and stockholders’ equity Liabilities and Equity [Abstract] State State and Local Jurisdiction [Member] Cover [Abstract] Cover [Abstract] Money market funds Cash and Cash Equivalents, Fair Value Disclosure Maximum Maximum [Member] Options exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Fee receivable for reduction in royalty rate Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Term Loans Debt Instrument [Line Items] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Amortization and depreciation Deferred Tax Assets, Amortization and Depreciation Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from amortization and depreciation. Adjustments to principal value Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Prior to first anniversary of closing date Debt Instrument, Redemption, Period One [Member] Potential commercialization milestones Collaborative Arrangement, Potential Commercialization Milestones Collaborative Arrangement, Potential Commercialization Milestones Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Entity Shell Company Entity Shell Company Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Schedule of Cash Flow, Supplemental Disclosures Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Potential common shares that would have been included if not for anti-dilutive effect of securities Potential Common Shares, Anti-Dilutive Effect On Securities Potential Common Shares, Anti-Dilutive Effect On Securities Texas TEXAS U.S. Income (Loss) from Continuing Operations before Income Taxes, Domestic Schedule of Stock-Based Compensation Recognized Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Current portion of operating lease liability Current portion of lease liabilities Less: Current portion of operating lease liability Operating Lease, Liability, Current Nontaxable or nondeductible items Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent [Abstract] Closing fee Debt Instrument, Closing Fee Amount Debt Instrument, Closing Fee Amount Document Fiscal Period Focus Document Fiscal Period Focus Total cash, cash equivalents and investments, Gross Unrealized Losses Cash Cash Equivalents And Investments Gross Unrealized Losses Cash, cash equivalents and investments gross unrealized losses. Award Timing Method Award Timing Method [Text Block] Litigation Case [Domain] Litigation Case [Domain] Award Type [Axis] Award Type [Axis] Percentage of royalty revenue Percentage Of Royalty Revenue Represents percentage of royalty revenue. Deferred revenue, non-current Beginning balance Ending balance Contract with Customer, Liability, Noncurrent Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Trading Symbol Trading Symbol 2029 Lessee, Operating Lease, Liability, to be Paid, Year Four Aggregate Intrinsic Value (in thousands) Stock Options, Aggregate Intrinsic Value [Abstract] Stock Options, Aggregate Intrinsic Value Changes in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Accrued expenses and other current liabilities Accrued expenses and other current liabilities Accrued Liabilities and Other Liabilities Entity Address, City or Town Entity Address, City or Town Cardinal Health Cardinal Health [Member] Cardinal Health Product supply delivered Contract With Customer, Liability, Revenue Recognized Cash Not Received, Current Contract With Customer, Liability, Revenue Recognized Cash Not Received, Current Commercial customers Accounts Receivable, Commercial Customer [Member] Accounts Receivable, Commercial Customer Deferred tax assets net of valuation allowance Deferred Tax Assets, Net of Valuation Allowance Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] RSUs Restricted stock units Restricted Stock Units (RSUs) [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] South Carolina SOUTH CAROLINA Entity Emerging Growth Company Entity Emerging Growth Company Options issued and outstanding balance, beginning (shares) Options issued and outstanding balance, ending (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Transaction costs Contract With Customer, Liability, Transaction Costs Contract With Customer, Liability, Transaction Costs Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Facility fee Debt Issuance Costs, Net Gross To Net Sales Accrual And Reserve Classification [Axis] Gross To Net Sales Accrual And Reserve Classification [Axis] Gross To Net Sales Accrual And Reserve Classification IBSRELA Product, IBSRELA [Member] Product, IBSRELA Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Number of new loans Debt Instrument, Number Of New Loans Debt Instrument, Number Of New Loans Schedule of Revenue Disaggregation of Revenue [Table Text Block] Potential development and commercialization milestones Collaborative Arrangement, Potential Development And Commercialization Milestones Represents the amount of future development and commercialization milestone under collaborative arrangements. Current Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Increase in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Issuance of common stock upon exercise of options Stock Issued During Period, Value, Stock Options Exercised Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Potential increase to shares reserved for inclusion of forfeited or unexercised options from prior plan Increase In Shares Reserved For Issuance, Maximum Shares To Be Issued Upon Inclusion Of Forfeited Or Unexercised Options Increase In Shares Reserved For Issuance, Maximum Shares To Be Issued Upon Inclusion Of Forfeited Or Unexercised Options Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Number of RSUs (in thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Provision for income taxes Effective tax rate Income Tax Expense (Benefit) Floating per annum rate (percent) Debt Instrument, Basis Spread on Variable Rate Accrued Expenses "Accrued Expenses, Policy [Policy Text Block] "Accrued Expenses, Policy Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Property and equipment, gross Property, Plant and Equipment, Gross Non-cash lease expense Operating Lease, Right-of-Use Asset, Periodic Reduction Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Options vest and expected to vest (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Nonvested balance, beginning (shares) Nonvested balance, ending (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Gross product revenue Revenue, Product and Service Benchmark [Member] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Potential increase in shares reserved as a percentage of shares outstanding Increase In Shares Reserved For Issuance, Option For Annual Increase As Percentage Of Shares Outstanding Increase In Shares Reserved For Issuance, Option For Annual Increase As Percentage Of Shares Outstanding Effective Income Tax Rate Reconciliation [Table] Effective Income Tax Rate Reconciliation [Table] Estimated useful lives Property, Plant and Equipment, Useful Life Schedule of Valuation Assumptions for Stock Options Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Prepaid commercial manufacturing Prepaid Commercial Manufacturing, Current Prepaid Commercial Manufacturing, Current PEO Total Compensation Amount PEO Total Compensation Amount Depreciation Depreciation Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Options vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Money market funds Money Market Funds [Member] After second anniversary to maturity date Debt Instrument, Redemption, Period Three [Member] Schedule of Gross To Net Adjustments of Revenue Schedule Of Gross To Net Sales Adjustments Of Revenue [Table Text Block] Schedule Of Gross To Net Sales Adjustments Of Revenue Minimum tax credit carryforwards Minimum Tax Credit Carryforward [Member] Minimum Tax Credit Carryforward [Member] Equity Components [Axis] Equity Components [Axis] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Product sales, net Product [Member] Number of reportable segments Number of Reportable Segments Number of options to extend Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Entity Address, State or Province Entity Address, State or Province Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] Prepaid product supply Contract With Customer, Liability, Revenue Invoiced As Prepayments For Product Supply, Noncurrent Contract With Customer, Liability, Revenue Invoiced As Prepayments For Product Supply, Noncurrent Total current liabilities Liabilities, Current Threshold percentage of net sales for tiered royalties Threshold Percentage of Sales For Tiered Royalties Represents the threshold percentage of net sales for tiered royalties. Individual: Individual [Axis] Compensation costs from contributions Defined Contribution Plan, Cost Income Tax Jurisdiction [Domain] Income Tax Jurisdiction [Domain] Document Annual Report Document Annual Report Research and development Research and Development Expense [Member] 2023 Open Market Sales Agreement Open Market Sales Agreement 2023, At The Market Offering [Member] Open Market Sales Agreement 2023, At The Market Offering Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Accrued sales and marketing expenses Accrued Sales And Marketing Expenses Amount of accrued sales and marketing expenses. Entity Interactive Data Current Entity Interactive Data Current Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Fosun Pharma Shanghai Fosun Pharmaceutical Industrial Development [Member] Represents Shanghai Fosun Pharmaceutical Industrial Development. Options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Reclassify amounts to be recognized in the next twelve months Contract With Customer, Liability, Revenue To Be Recognized In Next Twelve Months Contract With Customer, Liability, Revenue To Be Recognized In Next Twelve Months Stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount Less Segment Reconciliation [Abstract] U.S. treasury securities US Treasury Notes Securities [Member] Knight Agreement License Agreement Development Commercialization Distribution In Canada [Member] Agreement for the development, commercialization and distribution fo tenapanor in Canada. The Knight Agreement. Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Schedule of Total Unrecognized Stock-Based Compensation Expense, Net of Estimated Forfeitures Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block] Other assets Other Assets, Noncurrent Customer [Domain] Customer [Domain] Entity Central Index Key Entity Central Index Key PEO Name PEO Name Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Weighted-average share price (in dollars per share) Sale Of Stock, Weighted-Average Price Per Share Sale Of Stock, Weighted-Average Price Per Share Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Deferred revenue Beginning balance Ending balance Contract with Customer, Liability, Current Nontaxable or nondeductible items Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount [Abstract] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Additional details Lessee, Operating Lease, Description [Abstract] Exercise Price Award Exercise Price Entity Filer Category Entity Filer Category Income tax at the federal statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Non-cash Interest Expense on Deferred Royalty Obligation Non Cash Interest Expense On Deferred Royalty Obligation [Policy Text Block] Non Cash Interest Expense On Deferred Royalty Obligation Inventory, non-current Inventory, Noncurrent Deferred royalty obligation Deferred Tax Assets, Royalty Obligation Deferred Tax Assets, Royalty Obligation Deferred tax assets Deferred Tax Assets, Net [Abstract] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Percentage of non royalty revenue Percentage Of Non-Royalty Revenue Represents percentage of non-royalty revenue. Research and development Research and Development Expense Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Deferred Royalty Obligation [Roll Forward] Deferred Royalty Obligation [Roll Forward] Deferred Royalty Obligation Issuance of common stock for services Stock Issued Work in process Inventory, Work in Process, Gross Derivative Liabilities Derivative Instruments and Hedging Activities Disclosure [Text Block] Fair Value as of Grant Date Award Grant Date Fair Value Net operating loss carryforwards Operating Loss Carryforwards Exit fee (percent) Exit Fee, Percentage Exit Fee, Percentage Schedule of Long-Term Debt Borrowings Schedule of Long-Term Debt Instruments [Table Text Block] Granted (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Title and Position [Domain] Title and Position [Domain] Total costs and operating expenses Costs and Expenses Unrecognized Compensation Expense (in thousands) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Forfeited (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Offering sales commission (percent) Stock Issuance Cost, Commission, Percent Percentage of commission given on gross proceeds from sale of securities. Period to reduce royalty rate Collaborative Arrangement, Reduction In Royalty Rate, Period Collaborative Arrangement, Reduction In Royalty Rate, Period Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Counterparty Name [Domain] Counterparty Name [Domain] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Two Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Options issued and outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Other states Tax Authority, States Other Than California [Member] Tax Authority, States Other Than California AstraZeneca Astrazeneca [Member] Represents information pertaining to AstraZeneca. Non-PEO NEO Non-PEO NEO [Member] Options issued and outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Allowance for credit loss Debt Securities, Available-for-Sale, Allowance for Credit Loss Issuance of common stock under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan 2014 Plan Two Thousand Fourteen Equity Incentive Award Plan [Member] 2014 Equity Incentive Award Plan [Member] Number of payment tranches for fee receivable for reduction in royalty rate Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches Additional shares added (in shares) Common Stock, Additional Capital Shares Reserved For Future Issuance Common Stock, Additional Capital Shares Reserved For Future Issuance Sale of Stock [Axis] Sale of Stock [Axis] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Award Type [Domain] Award Type [Domain] 2026 Lessee, Operating Lease, Liability, to be Paid, Year One Allocated facilities, information technology, and human resources Allocated Facilities, Information Technology, And Human Resources Costs Allocated Facilities, Information Technology, And Human Resources Costs Equity Awards Adjustments Equity Awards Adjustments [Member] Leasehold improvements Leasehold Improvements [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Deferred Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Accrued compensation and benefits Increase (Decrease) in Employee Related Liabilities MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Foreign tax effects Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Fosun Agreement License Agreement Development Commercialization Distribution In China [Member] Agreement for the development, commercialization and distribution of tenapanor in China. The Fosun Agreement. Denominator Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Exit fee, net product revenue threshold Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum Revenues Revenues [Abstract] Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Investment in continuous unrealized loss position for more than one year Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions Section 162(m) limitation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Section 162(m) Limitation, Amount Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Section 162(m) Limitation, Amount Tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Amount [Abstract] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Other reconciliation items Segment Reporting, Other Reconciling Item, Amount Segment Reporting, Other Reconciling Item, Amount Financial Instruments [Domain] Financial Instruments [Domain] Unrealized gains (losses) on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Deferred tax liabilities Deferred Tax Liabilities, Gross Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Total Inventory, Net Minimum Minimum [Member] Royalty and commercialization milestone payments remitted to HCR Increase (Decrease) To Deferred Royalty Obligation, Royalty And Commercialization Milestone Payments Remitted Increase (Decrease) To Deferred Royalty Obligation, Royalty And Commercialization Milestone Payments Remitted Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Company Selected Measure Name Company Selected Measure Name Deferred Royalty Obligation Related to the Sale of Future Royalties Asset Retirement Obligation Disclosure [Text Block] Borrowing Debt Disclosure [Text Block] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Accounts payable Accounts Payable, Current Deferred tax liabilities Deferred Tax Liabilities, Net [Abstract] Cash paid for operating leases Operating Lease, Payments Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Office equipment and furniture Office Equipment And Furniture [Member] Office Equipment And Furniture [Member] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Potential development milestones Collaborative Arrangement, Potential Development Milestones Collaborative Arrangement, Potential Development Milestones Foreign Current Foreign Tax Expense (Benefit) Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Shares used in computing net loss per share - diluted (in shares) Weighted average common shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Fair value of options vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Derivative [Table] Derivative [Table] Entity Small Business Entity Small Business Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] State Current State and Local Tax Expense (Benefit) Document Transition Report Document Transition Report Schedule of Revenue from Customers as a Percentage of Total Product Revenue, Net Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Underlying Securities Award Underlying Securities Amount Equity Component [Domain] Equity Component [Domain] Healthcare royalty partners IV, L.P HealthCare Royalty Partners IV, L.P [Member] HealthCare Royalty Partners IV, L.P Document Period End Date Document Period End Date Weighted-Average Remaining Contractual Term (in years) Stock Options, Weighted Average Remaining Contractual Term [Abstract] Stock Options, Weighted Average Remaining Contractual Term Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Income Taxes Income Tax Disclosure [Text Block] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Rebates, Wholesaler and GPO Fees Contract With Customer, Rebates, Wholesaler And GPO Fees [Member] Contract With Customer, Rebates, Wholesaler And GPO Fees Options exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Operating lease liabilities Increase (Decrease) in Operating Lease Liability Non-cash interest expense Amortization of Debt Discount (Premium) Document Type Document Type Level 3 Fair Value, Inputs, Level 3 [Member] Net Loss Per Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Loss Contingencies [Table] Loss Contingencies [Table] Product and Service [Axis] Product and Service [Axis] Revenue Revenue from Contract with Customer Benchmark [Member] Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Options vested and expected to vest (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Total current assets Assets, Current Facilities Assets and Liabilities, Lessee [Abstract] Statistical Measurement [Axis] Statistical Measurement [Axis] Knight Knight Therapeutics Inc [Member] Represents information pertaining to Knight Therapeutics Inc. Number of lawsuits Loss Contingency, New Claims Filed, Number Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Current liabilities Liabilities, Current [Abstract] Tax credits Deferred Tax Assets, Tax Credit Carryforwards, Research Level 1 Fair Value, Inputs, Level 1 [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Collaboration and Licensing Agreements Collaboration and Licensing Agreements [Abstract] Accrued and other liabilities Increase (Decrease) in Accrued Liabilities Net loss per share of common stock - diluted (in dollars per share) Net loss per share of common stock - diluted (in dollars per share) Earnings Per Share, Diluted Other Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Supplementary disclosure of non-cash activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Loan agreement, covenant, sum of net product revenue and unrestricted cash as percentage of outstanding loan balance, calculation period (in months) Loan Agreement, Covenant, Sum Of Net Product Revenue And Unrestricted Cash As Percentage Of Outstanding Loan Balance, Calculation Period Loan Agreement, Covenant, Sum Of Net Product Revenue And Unrestricted Cash As Percentage Of Outstanding Loan Balance, Calculation Period Total Income Tax Paid, State and Local, after Refund Received Auditor Location Auditor Location Short-term investments Debt Securities, Available-for-Sale, Current Discounts and Chargebacks Contract With Customer, Discounts And Chargebacks [Member] Contract With Customer, Discounts And Chargebacks Domestic Tax Jurisdiction Domestic Tax Jurisdiction Domestic Tax Jurisdiction [Member] Imputed interest expenses Lessee, Operating Lease, Liability, Undiscounted Excess Amount Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Reclassify amounts to be recognized in the next twelve months Contract With Customer, Liability, Decrease In Revenue, To Be Recognized In Next Twelve Months Contract With Customer, Liability, Decrease In Revenue, To Be Recognized In Next Twelve Months Number of defendants Loss Contingency, Number of Defendants California California Franchise Tax Board [Member] Cash paid for income taxes Income Taxes Paid, Net Equity Incentive Plans Share-Based Payment Arrangement, Disclosure [Abstract] Income Tax Disclosure [Line Items] Income Tax Disclosure [Line Items] Income Tax Disclosure [Line Items] Upfront license fees Collaboration And Licensing Agreements, Upfront License Fees Collaboration And Licensing Agreements, Upfront License Fees Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Total principal Long-Term Debt, Gross Options granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Accrued compensation and benefits Employee-related Liabilities, Current Property and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Total undiscounted operating lease payments Lessee, Operating Lease, Liability, to be Paid Expiration Date Trading Arrangement Expiration Date Yankee bonds Debt Security, Government, Non-US [Member] Unrealized gains (losses) on available-for-sale securities Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Property and equipment, net Total property and equipment, net Property, Plant and Equipment, Net Numerator Net Income (Loss) Attributable to Parent [Abstract] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Accounts receivable Increase (Decrease) in Accounts Receivable Inventory Inventory, Policy [Policy Text Block] Entity Current Reporting Status Entity Current Reporting Status Accrued medical affairs expenses Accrued Medical Affairs Expenses, Current Accrued Medical Affairs Expenses, Current Derivative [Line Items] Derivative [Line Items] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Income tax at the federal statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Total cash, cash equivalents and investments, Gross Unrealized Gains Cash Cash Equivalents And Investments Gross Unrealized Gains Cash, cash equivalents and investments gross unrealized gains. Financial Instrument [Axis] Financial Instrument [Axis] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Executive Category: Executive Category [Axis] Research and development Research And Development Expense, Adjusted Research And Development Expense, Adjusted Stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent Amortization, effective interest rate, percent Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent State and local income taxes, net of federal effect (percent) Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Prepaid commercial manufacturing Increase (Decrease) In Prepaid Commercial Manufacturing Expense Increase (Decrease) In Prepaid Commercial Manufacturing Expense Current Fiscal Year End Date Current Fiscal Year End Date Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Weighted-Average Grant Date Fair Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Shares that may be issued upon exercise (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Non-cash royalty revenue related to the sale of future royalties Non-Cash Royalty Related To Sale of Future Royalties [Member] Non-Cash Royalty Related To Sale of Future Royalties Collaboration and Licensing Agreements Collaborative Arrangement Disclosure [Text Block] Weighted-average grant-date estimated fair value of options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Cash Cash [Member] Long-term debt Loans Payable, Noncurrent Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Schedule of Fair Value of Financial Assets Measured on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Balance as of January 1, Balance as of December 31, Unrecognized Tax Benefits Term Loans 2022 F and G Term Loan 2022 F And G [Member] Term Loan 2022 F And G Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Anti-dilutive securities not included in computation of diluted net loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Total cash, cash equivalents and investments Investments And Cash, Amortized Cost Investments And Cash, Amortized Cost McKesson Corporation McKesson Corporation [Member] McKesson Corporation Leases Lessee, Operating Leases [Text Block] Go v. Raab Go Versus Raab [Member] Go Versus Raab Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Measure: Measure [Axis] Schedule of Deferred Royalty Obligation Schedule Of Deferred Royalty Obligation [Table Text Block] Schedule Of Deferred Royalty Obligation Cencora (formerly AmerisourceBergen Drug Corporation) Cencora [Member] Cencora Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Cost of sales Cost of Product and Service Sold Gross-to-net sales accruals and reserves Contract With Customer, Gross To Net Sales Accrual [Roll Forward] Contract With Customer, Gross To Net Sales Accrual Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Entity Tax Identification Number Entity Tax Identification Number Retirement Savings Plan Pension and Other Postretirement Plans, Nonpension Benefits, Policy [Policy Text Block] Options issued and outstanding balance, beginning (in dollars per share) Options issued and outstanding balance, ending (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Common stock, shares issued (in shares) Common Stock, Shares, Issued Weighted-average remaining term (in years) Operating Lease, Weighted Average Remaining Lease Term Entity Public Float Entity Public Float Interest expense Interest Expense, Nonoperating Trading Arrangement: Trading Arrangement [Axis] Total Shareholder Return Amount Total Shareholder Return Amount Contingencies [Line Items] Loss Contingencies [Line Items] Loan agreement covenant, sum of net product revenue and unrestricted cash as percentage of outstanding loan balance, minimum Loan Agreement, Covenant, Sum of Net Product Revenue and Unrestricted Cash As Percentage Of Outstanding Loan Balance, Minimum Loan Agreement, Covenant, Sum Of Net Product Revenue And Unrestricted Cash As Percentage Of Outstanding Loan Balance, Minimum Non-cash interest expense related to the sale of future royalties Non-Cash Interest Expense Related To Sale Of Royalties Non-Cash Interest Expense Related To Sale Of Royalties Security Exchange Name Security Exchange Name METiS Therapeutics Inc METiS Therapeutics Inc [Member] METiS Therapeutics Inc Changes in estimated fair value Exit Fee 2022 [Member] Exit Fee 2022 Costs and operating expenses Operating Expenses [Abstract] Other Other Liabilities, Current Statement [Line Items] Statement [Line Items] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Fair value Cash and Cash Equivalent Research and development tax credit Research Tax Credit Carryforward [Member] Number of shares added to initial reserve Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Common Stock Common Stock [Member] Vested (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Statistical Measurement [Domain] Statistical Measurement [Domain] Share of common stock subject to issued inducement grants Common Stock Subject To Issued Inducement Grants, Shares Common Stock Subject To Issued Inducement Grants, Shares Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Summary of Additional Details of the Leases Schedule of Additional Details of Leases [Table Text Block] The tabular disclosure of additional details of the leases. Leases [Abstract] Leases [Abstract] Additions based on tax positions related to prior year Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Accounts payable Increase (Decrease) in Accounts Payable Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Net loss per share of common stock - basic (in dollars per share) Net loss per share of common stock - basic (in dollars per share) Earnings Per Share, Basic Commercial paper Commercial Paper [Member] Inventory Inventory, Gross Common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Deferred tax assets Deferred Tax Assets, Gross Schedule of Information Regarding Operating Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Inventory Disclosure [Abstract] Schedule of Securities Classified as Cash, Cash Equivalents and Short-Term Investments Cash, Cash Equivalent, and Investment [Table Text Block] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Payment to be received Revenue, Remaining Performance Obligation, Amount Copay Assistance and Returns Contract With Customer, Copay and Returns [Member] Contract With Customer, Copay and Returns Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Stock-based compensation Share-Based Payment Arrangement, Expense Current assets Assets, Current [Abstract] Options forfeited or canceled (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Total liabilities and stockholders’ equity Liabilities and Equity Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Number of Shares (in thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Other Deferred Tax Assets, Other Royalty payments and commercial milestone payments Increase (Decrease) in Royalties Payable Beginning balance Ending balance Contract With Customer, Gross To Net Sales Accruals Contract With Customer, Gross To Net Sales Accruals Accounting Policies [Abstract] Accounting Policies [Abstract] Summary of Undiscounted Cash Payment Obligations for Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Kyowa Kirin Kyowa Kirin Co. Ltd [Member] Represents the information pertaining to Kyowa Kirin Co., Ltd. Estimated fair value of RSUs vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Pay vs Performance Disclosure [Line Items] Total operating lease liabilities Operating Lease, Liability U.S. government-sponsored agency bonds US Government Agencies Debt Securities [Member] Issuance of common stock for services (in shares) Issuance of common stock for services (in shares) Stock Issued During Period, Shares, Issued for Services Deferred revenue Increase (Decrease) in Deferred Revenue Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Company Selected Measure Amount Company Selected Measure Amount 2028 Lessee, Operating Lease, Liability, to be Paid, Year Three Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Name Measure Name Thereafter Lessee, Operating Lease, Liability, To Be Paid, After Year Four Lessee, Operating Lease, Liability, To Be Paid, After Year Four Total long-term debt Long-Term Debt Total assets Assets Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Geographical [Domain] Geographical [Domain] Income Taxes Income Tax, Policy [Policy Text Block] Operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Receivable Type [Axis] Receivable Type [Axis] Research and development tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Other segment expenses Segment Reporting, Other Segment Item, Amount Accrued payments due to AstraZeneca Accrued Payments Due To Third-Party Accrued Payments Due To Third-Party Concentration Risk Type [Axis] Concentration Risk Type [Axis] Inventory Inventory Disclosure [Text Block] Assets Assets, Fair Value Disclosure [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Right-of-use assets obtained in exchange for lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Lease costs Lease, Cost [Abstract] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Level 2 Fair Value, Inputs, Level 2 [Member] Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] State and local income taxes, net of federal effect Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Final fee Debt Instrument, Fee Amount ​Operating Leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Schedule of Components of Provision for Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Plan Name [Axis] Plan Name [Axis] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] PEO PEO [Member] Proceeds from 2022 Loan Agreement, net of costs Proceeds from Issuance of Secured Debt United States UNITED STATES Changes in operating assets and liabilities Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Changes in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Accumulated Deficit Retained Earnings [Member] Income Tax Jurisdiction [Axis] Income Tax Jurisdiction [Axis] Schedule of Accrued Expenses and Other Current Liabilities Schedule of Accrued Liabilities [Table Text Block] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement [Abstract] Income Statement [Abstract] Sale of Stock [Domain] Sale of Stock [Domain] Gross To Net Sales Accrual And Reserve Classification [Domain] Gross To Net Sales Accrual And Reserve Classification [Domain] Gross To Net Sales Accrual And Reserve Classification [Domain] Products and Services [Domain] Product and Service [Domain] Customer Customer Concentration Risk [Member] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] 2022 Term Loan Term Loan 2022 [Member] Term Loan 2022 Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] City Area Code City Area Code Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Schedule of Deferred Revenue Balances Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] General and administrative General and Administrative Expense Investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Effective Income Tax Rate Reconciliation [Line Items] Effective Income Tax Rate Reconciliation [Line Items] Selling, general and administrative Selling, General and Administrative Expenses [Member] Summary of Lease Costs Lease, Cost [Table Text Block] Payments of the previously outstanding exit fees Exit fee payment Payments for Derivative Instrument, Financing Activities Federal Deferred Federal Income Tax Expense (Benefit) Reconciliation of Unrecognized Tax Benefits Unrecognized Tax Benefits [Roll Forward] Auditor Name Auditor Name Issuance of common stock for services Stock Issued During Period, Value, Issued for Services Total cash, cash equivalents and investments, Fair Value Investments and Cash Nature of Operations Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Supplementary disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Other Performance Measure, Amount Other Performance Measure, Amount Weighted-Average Exercise Price per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Prepayment premium (as a percent) Debt Instrument, Prepayment Fee, Percentage The percentage of fee payable on prepayment of debt. Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Amount Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] Additional paid-in capital Additional Paid in Capital, Common Stock Net cash used in investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activity Document Fiscal Year Focus Document Fiscal Year Focus Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Right-of-use assets Right-of-use assets Operating Lease, Right-of-Use Asset Effective tax rate Effective Income Tax Rate Reconciliation, Percent Subtractions based on tax positions related to prior year Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Operating lease expense Operating Lease, Cost Plan Name [Domain] Plan Name [Domain] Average Remaining Vesting Period (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Issuance of common stock upon exercise of options (in shares) Options exercised (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Valuation allowance Deferred Tax Assets, Valuation Allowance North America North America [Member] Segment Reporting Segment Reporting Disclosure [Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] U.S. treasury securities US Treasury Securities [Member] Summary of significant accounting policies New Accounting Pronouncements or Change in Accounting Principle [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] John Bishop [Member] John Bishop Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Accrued gross to net revenue liabilities Accrued Gross To Net Revenue Liabilities Accrued Gross To Net Revenue Liabilities Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Leases Lessee, Leases [Policy Text Block] Selling, general and administrative Selling, General and Administrative Expense Depreciation and amortization expense Depreciation, Depletion and Amortization ESPP ESPP shares issuable Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Finished goods Inventory, Finished Goods, Gross Accounts Receivable Accounts Receivable [Policy Text Block] Foreign tax effects Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Arrangement Duration Trading Arrangement Duration Segments [Axis] Segments [Axis] AZ Termination Agreement AstraZeneca Termination Agreement [Member] AstraZeneca Termination Agreement Local Phone Number Local Phone Number Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Common stock closing price (in dollars per share) Share Price Other, net Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Other Item Equity Incentive Plans Share-Based Payment Arrangement [Text Block] Reportable Segment Reportable Segment [Member] Reportable Segment Assets Assets [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Debt Instrument [Axis] Debt Instrument [Axis] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Fair Value Measurements Fair Value Disclosures [Text Block] Stockholders’ equity Equity, Attributable to Parent [Abstract] Interest rate Debt Instrument, Interest Rate, Stated Percentage Short-term investments Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract] Operating lease liability, net of current portion Operating lease liability, net of current portion Operating Lease, Liability, Noncurrent Entity Voluntary Filers Entity Voluntary Filers Loss before provision for income taxes Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Entity Registrant Name Entity Registrant Name Product supply revenue Product Supply Revenue [Member] Product Supply Revenue Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] After first anniversary through second anniversary of closing date Debt Instrument, Redemption, Period Two [Member] Other State and Local Tax Jurisdiction, Other [Member] Total Assets, Fair Value Disclosure Number of operating segments Number of Operating Segments Term Loan 2022 F Term Loan 2022 F [Member] Term Loan 2022 F Audit Information [Abstract] Audit Information Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Percent [Abstract] Upfront payment received Proceeds from License Fees Received Proceeds from the sale of future royalties, net of issuance costs Proceeds From Sale Of Future Royalties, Net Of Issuance Costs Proceeds From Sale Of Future Royalties, Net Of Issuance Costs Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Restatement Determination Date: Restatement Determination Date [Axis] Final fee due upon maturity, acceleration, prepayment, or termination (percent) Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage Provision for income taxes Income Tax Expense (Benefit), Continuing Operations [Abstract] Proceeds from milestone payments Revenue, Remaining Performance Obligation, Variable Consideration Amount Revenue, Remaining Performance Obligation, Variable Consideration Amount Name Trading Arrangement, Individual Name Term loan face amount Debt Instrument, Face Amount Name Awards Close in Time to MNPI Disclosures, Individual Name Accrued Expenses and Other Current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Nonvested balance, beginning (in dollars per share) Nonvested balance, ending (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Non-Current Change In Contract With Customer Liability, Noncurrent, Rollforward [Roll Forward] Change In Contract With Customer Liability, Noncurrent, Rollforward Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Term A Loan Term Loan 2022 A [Member] Term Loan 2022 A ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag 2017 KKC Agreement License Agreement Development Commercialization Distribution In Japan [Member] Agreement for the development, commercialization and distribution of tenapanor in Japan. The 2017 KKC Agreement. Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Options vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Litigation Case [Axis] Litigation Case [Axis] Foreign Foreign Tax Jurisdiction [Member] Auditor Firm ID Auditor Firm ID Segments [Domain] Segments [Domain] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Inventory Increase (Decrease) in Inventories Less: Current portion of long-term debt Loans Payable, Current Other Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Net Loss per Share Earnings Per Share, Policy [Policy Text Block] Advance Royalties [Abstract] Income Tax Disclosure [Table] Income Tax Disclosure [Table] Income Tax Disclosure [Table] All Executive Categories All Executive Categories [Member] Schedule of Components of Deferred Tax Assets Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Common stock, $0.0001 par value per share; 500,000,000 shares authorized; 244,351,501 and 238,015,825 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively Common Stock, Value, Issued Title and Position [Axis] Title and Position [Axis] Commitments and contingencies (Note 19) Commitments and Contingencies Provisions Contract With Customer, Gross To Net Sales, Provisions Contract With Customer, Gross To Net Sales, Provisions Term loan Loans Payable [Member] Accounting Standards Update and Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Schedule of Revenue by Geographic Areas Revenue from External Customers by Geographic Areas [Table Text Block] Net deferred taxes Deferred Tax Assets, Net PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Collaboration partners Collaboration Partnership Concentration Risk [Member] Collaboration Partnership Concentration Risk Revenue from Contract with Customer [Abstract] Schedule of Reconciliation of Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Short-Term Investments Short Term Investments [Policy Text Block] Short term investments. Cash and cash equivalents Cash and Cash Equivalent [Abstract] Derivative Contract [Domain] Derivative Contract [Domain] Net operating loss carryforwards, indefinite Operating Loss Carryforwards, Without Expiration Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws indefinitely. Proceeds from issuance of common stock in at the market offering, net of issuance costs Gross proceeds Proceeds from Issuance of Common Stock All Individuals All Individuals [Member] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Name Forgone Recovery, Individual Name Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Proceeds from issuance of common stock under equity incentive plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised BioRidge Pharma, LLC BioRidge Pharma, LLC [Member] BioRidge Pharma, LLC Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Geographical [Axis] Geographical [Axis] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Proceeds received from HCR Increase (Decrease) To Deferred Royalty Obligation, Proceeds Received Increase (Decrease) To Deferred Royalty Obligation, Proceeds Received Asia Pacific Asia Pacific [Member] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Title of 12(b) Security Title of 12(b) Security Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Current Change In Contract With Customer Liability, Current, Rollforward [Roll Forward] Change In Contract With Customer Liability, Current, Rollforward Earnings Per Share [Abstract] Earnings Per Share [Abstract] Other income, net Nonoperating Income (Expense) Prepaid commercial manufacturing, non-current Prepaid Commercial Manufacturing, Non Current Prepaid Commercial Manufacturing, Non Current Maximum shares to be issued under ESPP Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Number Of Shares Under Employee Stock Purchase Plan Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Number Of Shares Under Employee Stock Purchase Plan Floor Rate Secured Overnight Financing Rate (SOFR) Floor Rate [Member] Secured Overnight Financing Rate (SOFR) Floor Rate Collaborators Accounts Receivable, Collaborator [Member] Accounts Receivable, Collaborator Schedule of Anti-Dilutive Securities Not Considered in Diluted Net Loss Per Common Share Calculation Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Deferred royalty obligation related to the sale of future royalties Deferred royalty obligation balance as of January 1, Deferred royalty obligation balance as of December 31, Deferred Royalty Obligation, Noncurrent Deferred Royalty Obligation, Noncurrent Tax credit carryforwards Tax Credit Carryforward, Amount Stock-based compensation Share-Based Payment Arrangement, Expense, Adjusted Share-Based Payment Arrangement, Expense, Adjusted Term C Loan Term Loan 2022 C [Member] Term Loan 2022 C Options exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Product supply delivered Contract With Customer, Liability, Revenue Recognized Cash Not Received, Noncurrent Contract With Customer, Liability, Revenue Recognized Cash Not Received, Noncurrent Maximum potential payment per agreement Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum Award Timing Disclosures [Line Items] Schedule of Current Inventory Schedule of Inventory, Current [Table Text Block] Term of lease extension Lessee, Operating Lease, Renewal Term Stockholders' Equity Equity [Text Block] Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Net favorable adjustment from changes in prior periods' estimates Contract With Customer, Gross To Net Sales, Provisions, Favorable Adjustments From Changes In Prior Period Estimates Contract With Customer, Gross To Net Sales, Provisions, Favorable Adjustments From Changes In Prior Period Estimates 2025 Open Market Sales Agreement Open Market Sales Agreement 2025, At The Market Offering [Member] Open Market Sales Agreement 2025, At The Market Offering Schedule of Reconciliation of Effective Tax Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Adoption Date Trading Arrangement Adoption Date Inducement Plan Two Thousand Sixteen Employment Commencement Incentive Plan [Member] 2016 Employment commencement incentive plan. Reclassification Reclassification, Comparability Adjustment [Policy Text Block] Lease terms Lessee, Operating Lease, Term of Contract Credits/payments Contract With Customer, Gross To Credits Or Deductions Issued Contract With Customer, Gross To Credits Or Deductions Issued Customer [Axis] Customer [Axis] Loss from operations Operating Income (Loss) Stock-Based Compensation Compensation Related Costs, Policy [Policy Text Block] Accumulated deficit Retained Earnings (Accumulated Deficit) Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Prepaid commercial manufacturing Prepaid Commercial Manufacturing Prepaid Commercial Manufacturing Future payment obligation, excluding interest payments Long-Term Debt, Excluding Interest Payments Long-Term Debt, Excluding Interest Payments Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Term B Loan Term Loan 2022 B [Member] Term Loan 2022 B Non-cash interest expense related to the sale of future royalties Increase (Decrease) To Deferred Royalty Obligation, Non-Cash Interest Expense Related To Sale Of Future Royalties Increase (Decrease) To Deferred Royalty Obligation, Non-Cash Interest Expense Related To Sale Of Future Royalties Payables and Accruals [Abstract] Payables and Accruals [Abstract] Statement [Table] Statement [Table] Total deferred Deferred Income Tax Expense (Benefit) Adjustments to reconcile net loss to net cash used in operating activities Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Variable Rate [Domain] Variable Rate [Domain] Upfront payment Contract with Customer, Liability Massachusetts MASSACHUSETTS All Adjustments to Compensation All Adjustments to Compensation [Member] Amendment Flag Amendment Flag Termination Date Trading Arrangement Termination Date Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Receivable [Domain] Receivable [Domain] Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Selling expenses Selling Expense Shares used in computing net loss per share - basic (in shares) Weighted average common shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic New Jersey NEW JERSEY Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule of Computation of Net Loss Per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Board of directors Director [Member] Options exercisable (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Segment Reporting [Abstract] Cost of revenue Cost of Revenue Debt Disclosure [Abstract] Debt Disclosure [Abstract] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Other Increase (Decrease) To Deferred Royalty Obligation, Other Increase (Decrease) To Deferred Royalty Obligation, Other Term Loan 2022 G Term Loan 2022 G [Member] Term Loan 2022 G Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Term D Loan Term Loan 2022 D [Member] Term Loan 2022 D Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Right-of-use asset Deferred Tax Liabilities, Right Of Use Asset Amount of deferred tax liability attributable to taxable temporary differences from right of use asset. Accrued contract manufacturing expenses Accrued Contract Manufacturing Expenses, Current Accrued Contract Manufacturing Expenses, Current Options granted (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Use of Estimates Use of Estimates, Policy [Policy Text Block] Schedule of Valuation Assumptions for Employee Stock Purchase Plan Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Exit Fee 2018 Exit Fee 2018 [Member] Exit Fee 2018 Insider Trading Arrangements [Line Items] Section 162(m) limitation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Section 162(m) Limitation, Percent Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Section 162(m) Limitation, Percent Options forfeited or canceled (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Other cost of revenue Product and Service, Other [Member] Raw materials Inventory, Raw Materials, Gross Total liabilities Liabilities Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Product Concentration Risk Product Concentration Risk [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Additions based on tax positions related to current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Term E Loan Term Loan 2022 E [Member] Term Loan 2022 E Proceeds from maturities and redemptions of investments Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Michael Raab [Member] Michael Raab Ardelyx, Inc. Stockholder Derivative Litigation Ardelyx, Inc. Stockholder Derivative Litigation [Member] Ardelyx, Inc. Stockholder Derivative Litigation Issuance of common stock in at-the-market offering Stock Issued During Period, Value, New Issues Asset-backed securities Asset-Backed Securities [Member] Kentucky KENTUCKY Variable Rate [Axis] Variable Rate [Axis] Laboratory equipment Laboratory Equipment [Member] Laboratory Equipment [Member] Counterparty Name [Axis] Counterparty Name [Axis] Schedule of Restricted Stock Units Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Fair Value Assets Debt Securities, Available-for-Sale Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Maximum aggregate offering price Maximum Aggregate Offering Price Amount of maximum aggregate offering price. Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-NEOs Non-NEOs [Member] Corporate bonds Corporate Debt Securities [Member]